Comprehensive Study Notes: Polycystic Ovary Syndrome (PCOS)

Overview and Etiological Factors of PCOS

  • Definition & Nomenclature:

    • Polycystic Ovary Syndrome (PCOS) is a complex medical condition characterized by a group of symptoms, diverse clinical presentations, and multiple underlying pathophysiological mechanisms.
    • Previously referred to as Stein-Leventhal syndrome.
  • Etiological Factors:

    • Genetic Factors: Operates as a complex genetic trait, with key susceptibility loci identified on:
    • Chromosome no. 2
    • Chromosome no. 9
    • Environmental Factors: External environmental exposures contributing to metabolic and endocrine dysfunction.
    • Lifestyle Factors: Diet, physical activity, and related behavioral factors.
  • Primary Pathophysiological Cascades:

    1. Excessive androgen production
    2. Defect in folliculogenesis
    3. Defect in insulin action (Insulin resistance)
    4. Defect in gonadotropin secretion and action
    5. Obesity

Flowchart showing the pathophysiology and etiological factors of PCOS

Hyperandrogenism and Androgen Excess

  • Anatomical Sources of Androgens:

    • Ovaries: Function as the primary and main source of excessive androgen production in PCOS.
    • Adrenal Glands: Provide a minor contribution, leading to elevated Dehydroepiandrosterone sulfate (↑DHEA-S\uparrow\text{DHEA-S}) levels.
  • Circulating Androgen Level Thresholds:

    • Normal Females: Serum androgen levels are <70 ng/dL< 70\,\text{ng/dL}.
    • PCOS Patients: Serum androgen levels range from ≥70 ng/dL\ge 70\,\text{ng/dL} to <200 ng/dL< 200\,\text{ng/dL}.
    • Clinical Manifestation: Androgen levels within the ≥70 ng/dL\ge 70\,\text{ng/dL} to <200 ng/dL< 200\,\text{ng/dL} range directly manifest as hirsutism.
  • Folliculotoxicity of Androgens:

    • High local intraovarian androgen concentrations exert a direct toxic effect on developing ovarian follicles.
    • Causes complete arrest of follicular growth.
    • Prevents maturation of primary and secondary follicles into fully mature Graafian follicles.
  • Cardiovascular and Metabolic Complications of Androgen Excess:

    • Dyslipidemia: Characterized by elevated low-density lipoprotein (↑LDL\uparrow\text{LDL}) and decreased high-density lipoprotein (↓HDL\downarrow\text{HDL}).
    • Increased overall risk of developing coronary heart disease.

Ovarian Manifestations and Ultrasonographic (USG) Findings

  • Morphological Characteristics on Ultrasonography:
    • Characterized by small, unruptured follicles (pathologically distinct from true ovarian cysts) arranged systematically along the peripheral margin of the ovary.
    • Classically described as a "Necklace appearance".

Ultrasound image displaying polycystic ovarian morphology with peripheral follicles

  • Quantitative Criteria for Polycystic Ovarian Morphology:
    • Rotterdam Criteria:
    • Presence of ≥12\ge 12 follicles per ovary.
    • Follicular size measuring 2−9 mm2-9\,\text{mm} in diameter.
    • Total volume of one or both ovaries ≥10 cc\ge 10\,\text{cc}.
    • American and European Societies Criteria:
    • Presence of >20> 20 follicles measuring 2−9 mm2-9\,\text{mm} in diameter.
    • Clinical Note: Ovaries may appear ultrasonographically normal in a subset of patients with confirmed PCOS.

Dysregulation of Gonadotropins and Ovulatory Dysfunction

  • Hypothalamic-Pituitary-Ovarian Axis Pathophysiology:

    • GnRH Dynamics: Increased pulse frequency of Gonadotropin-Releasing Hormone (GnRH) released from the hypothalamus.
    • Pituitary Secretion: High-frequency GnRH pulses selectively drive increased Luteinizing Hormone (↑LH\uparrow\text{LH}) secretion by the anterior pituitary gland.
    • Ovarian Response: Causes marked theca cell hyperplasia in the ovaries.
  • LH Dynamics and Altered Gonadotropin Ratios:

    • Tonic, persistently elevated LH levels throughout the entire menstrual cycle.
    • Complete absence of the mid-cycle LH surge required for follicular rupture.
    • FSH : LH Ratio:
    • Normal Female Ratio: 1:11:1
    • PCOS Ratio: 1:21:2 or 1:31:3
    • Follicle-Stimulating Hormone (FSH) levels remain strictly normal, while LH levels are significantly increased.
    • Optimal Diagnostic Timing: The ideal time window to evaluate serum LH and FSH levels is on Day 2 or Day 3 of the menstrual cycle.
  • Mechanisms of Anovulation in PCOS:

    • Dual underlying mechanisms cause continuous anovulation:
    1. Direct folliculotoxicity driven by local androgen excess.
    2. Complete absence of the pre-ovulatory LH surge.
  • Clinical Manifestations of Ovulatory Dysfunction:

    • Infertility due to persistent anovulation.
    • Severely decreased progesterone levels (↓Progesterone\downarrow\text{Progesterone}) resulting from the total failure of corpus luteum formation.
    • Development of secondary (2∘2^\circ) amenorrhea or oligomenorrhea (defined as <9< 9 menstrual cycles per year).
    • Increased risk of spontaneous abortions during pregnancy.

Insulin Resistance, Acanthosis Nigricans, and HAIR-AN Syndrome

  • Pathophysiology of Insulin Resistance in PCOS:

    • Insulin resistance occurs independently of patient obesity status:
    • Present in 70%70\% of obese PCOS patients.
    • Present in 30%30\% of non-obese (thin/lean) PCOS patients.
    • Mechanisms leading to hyperandrogenism:
    • Drives theca cell hyperplasia in the ovarian stroma.
    • Induces overall oversensitivity to LH stimulation due to the loss of the normal physiological ceiling/cut-off mechanism (normally, LH stimulates androgen production from theca cells up to a controlled limit).
    • Directly contributes to systemic dyslipidemia.
  • Acanthosis Nigricans:

    • Serves as the primary cutaneous clinical manifestation of systemic insulin resistance.
    • Characterized by dark, velvety, hyperpigmented, and thickened skin patches.
    • Typical anatomical sites of distribution:
    • Nape of the neck
    • Axillary region
    • Groin folds
    • Infra-mammary folds (under breast tissue)
  • HAIR-AN Syndrome:

    • Acronym representing a specific severe subtype of PCOS:
    • H / A: Hyper Androgenism
    • I / R: Insulin Resistance
    • A / N: Acanthosis Nigricans
  • Applied Diagnostic Protocols for Insulin Resistance:

    • Baseline Screening: All patients diagnosed with PCOS must undergo an Oral Glucose Tolerance Test (OGTT) every 22 years.
    • Positive Finding: If insulin resistance is detected (⊕\oplus), the OGTT must be repeated annually (every 11 year).

Role of Obesity, Estrogen Metabolism, and Menstrual Abnormalities

  • Prevalence & Pathophysiology of Obesity:

    • Present in 40−80%40-80\% of PCOS patients.
    • Obesity is not a defining diagnostic feature; PCOS can occur in thin/lean individuals.
    • Exacerbates systemic metabolic abnormalities by:
    • Aggravating insulin resistance.
    • Worsening dyslipidemia.
  • Peripheral Conversion & Estrogen Dynamics:

    • Adipose tissue contains high concentrations of the enzyme aromatase.
    • Circulating hyperandrogens are converted in peripheral adipocytes by aromatase into estrone (E1E_1), resulting in marked elevations of estrone (↑E1\uparrow E_1).
    • Estradiol to Estrone (E2:E1E_2 : E_1) Ratio:
    • Normal Females: 2:12:1
    • Obese PCOS Females: 1:21:2

Flowchart outlining obesity pathophysiology and menstrual cycle abnormalities in PCOS

  • Menstrual Presentation by Phenotype:
    • Thin PCOS Patient: Most commonly presents with secondary (2∘2^\circ) amenorrhea (maintains normal baseline estrogen levels).
    • Obese PCOS Patient: Presents with secondary (2∘2^\circ) amenorrhea or menometrorrhagia (heavy, irregular bleeding caused by unopposed estrone-mediated estrogen breakthrough bleeding).

Comprehensive Hormonal Profile in PCOS

  • Summary of Biochemical Biomarkers in PCOS:

  | Serum Biomarker | Change in PCOS | Underlying Mechanism / Clinical Notes |   | :--- | :--- | :--- |   | Testosterone | Increased (↑\uparrow) | Driven by ovarian theca cell hyper-responsiveness and hyperplasia |   | DHEA-S | Increased (↑\uparrow) | Minor contribution from adrenal hypersecretion |   | LDL | Increased (↑\uparrow) | Component of metabolic dyslipidemia |   | AMH (Anti-Müllerian Hormone) | Increased (↑≥3 ng/mL\uparrow\ge 3\,\text{ng/mL}) | Directly proportional to the increased pool of small pre-antral/antral follicles |   | Estrone (E1E_1) | Increased (↑\uparrow) | Elevated specifically in obese PCOS patients due to peripheral adipose aromatization |   | LH | Increased (↑\uparrow) | Driven by increased hypothalamic GnRH pulse frequency |   | FSH | Unchanged (Normal) | Pituitary secretion remains baseline |   | Estradiol (E2E_2) | Unchanged (Normal) | Baseline secretion maintained without mid-cycle surge |   | Prolactin | Unchanged (Normal) | Unaffected baseline levels |   | TSH | Unchanged (Normal) | Unaffected baseline thyroid axis |   | HDL | Decreased (↓\downarrow) | Secondary to androgen excess and insulin resistance |   | Progesterone | Decreased (↓\downarrow) | Absence of luteinization and corpus luteum formation due to anovulation |   | SHBG (Sex Hormone Binding Globulin) | Decreased (↓\downarrow) | Synergistically suppressed by hyperandrogenemia and hyperinsulinemia |

Gonadotropin secretion defect and hormonal profile in PCOS

Diagnostic Criteria (Rotterdam Criteria) and Differential Diagnosis

  • Rotterdam Criteria:

    • Diagnosis requires the presence of at least 2 out of 3 of the following criteria to establish a provisional diagnosis of PCOS:
    1. Androgen Excess:
      • Biochemically: Hyperandrogenemia (elevated serum testosterone levels).
      • Clinically: Hyperandrogenism (hirsutism).
    2. Ovulatory Dysfunction: Manifesting as secondary (2∘2^\circ) amenorrhea or oligomenorrhea.
    3. Polycystic Appearance of Ovaries on USG: Presence of ≥12\ge 12 follicles measuring 2−9 mm2-9\,\text{mm} in diameter in one or both ovaries, OR an ovarian volume ≥10 cc\ge 10\,\text{cc}.
  • Differential Diagnosis — Rule Out Late-Onset Congenital Adrenal Hyperplasia (CAH):

    • Following a provisional diagnosis of PCOS, serum 17-OH progesterone17\text{-OH progesterone} levels must be evaluated as a primary screening test:
    • Level <200 ng/dL< 200\,\text{ng/dL}: Late-onset CAH is definitively ruled out.
    • Level 200−800 ng/dL200-800\,\text{ng/dL}: Equivocal result; mandates an ACTH Stimulation Test (the gold-standard diagnostic test):
      • Confirms late-onset CAH if positive.
      • Rules out late-onset CAH if negative.
    • Level >800 ng/dL> 800\,\text{ng/dL}: Late-onset CAH is confirmed.
  • Parameters EXCLUDED from PCOS Diagnostic Criteria:

    • The following parameters are clinical/pathophysiological associations but are NOT part of the formal diagnostic criteria for PCOS:
    1. Obesity
    2. Altered LH : FSH ratio
    3. Insulin resistance
    4. Menometrorrhagia
    5. "Necklace appearance" on USG

Clinical Complications and Management Considerations

  • Short-Term Consequences & Complications:

    • Menstrual irregularities (oligomenorrhea, secondary amenorrhea, menometrorrhagia)
    • Hirsutism
    • Alopecia
    • Infertility
    • Systemic insulin resistance
  • Long-Term Potential Complications:

    • Endometrial Cancer: Significantly heightened risk driven by chronic, unopposed estrogen stimulation (↑\uparrow estrogen / estrone without cyclic progesterone balance).
    • Ovarian Cancer: Unclear/variable association (+/−+/-).
    • Non-Alcoholic Steatohepatitis (NASH): Secondary to obesity and metabolic syndrome.
    • Cardiovascular Disease: Secondary to chronic dyslipidemia (↑LDL\uparrow\text{LDL}, ↓HDL\downarrow\text{HDL}) and aggravated insulin resistance.
  • Standard Diagnostic Workup for PCOS Presenting with Secondary (2∘2^\circ) Amenorrhea:

    • Urine Pregnancy Test (UPT): Negative
    • Serum LH: Elevated (↑\uparrow)
    • Serum FSH: Normal